NASDAQ: CNTXContext Therapeutics Inc Stock
$0.63-0.02 (-3.08%)
Updated Jun 13, 2025
CNTX Price
$0.63
Fair Value Price
$1.61
Market Cap
$56.42M
52 Week Low
$0.49
52 Week High
$2.75
P/E
-2.03x
P/B
0.62x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$27.63M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$15M
Beta
0.96
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CNTX Overview
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cancer treatments for women. Candidates include ONA-XR (onapristone extended release) to treat female hormone-dependent cancers, and CLDN6xCD3 bsAb, intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6 (Claudin 6). The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics was incorporated in 2015 and is headquartered in Philadelphia, PA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNTX's potential to beat the market
- CNTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CNTX
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important CNTX news, forecast changes, insider trades & much more!
CNTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNTX ($0.63) is undervalued by 61% relative to our estimate of its Fair Value price of $1.61 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CNTX ($0.63) is significantly undervalued by 61% relative to our estimate of its Fair Value price of $1.61 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CNTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CNTX due diligence checks available for Premium users.
Valuation
CNTX fair value
Fair Value of CNTX stock based on Discounted Cash Flow (DCF)
Price
$0.63
Fair Value
$1.61
Undervalued by
60.94%
CNTX ($0.63) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CNTX ($0.63) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CNTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CNTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.03x
Industry
-108.97x
Market
31.36x
CNTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.62x
Industry
4.66x
CNTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.6M
Profit Margin
0%
CNTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$93.0M
Liabilities
$2.0M
Debt to equity
0.02
CNTX's short-term assets ($92.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNTX's short-term assets ($92.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.0M
Investing
-$33.9k
Financing
-$15.3k
CNTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNTX vs Biotech Stocks
Context Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.